Daniel M Labow, MD
- PROFESSOR | Surgery
Specialties:Surgical Oncology, Surgery
Daniel M. Labow, M.D., Chief of the Surgical Oncology Division at Mount Sinai Hospital, is a board-certified Surgeon with a specialty in Surgical Oncology. He has established himself at Mount Sinai Hospital since 2004 after studying medicine at a unique, combined medical school, the Dartmouth-Brown Medical Program, completing his General Surgery residency at the University of Chicago, and receiving his fellowship training at Memorial Sloan-Kettering Cancer Center. As Vice Chair of Outpatient Services for the Department of Surgery, Dr. Labow continuously designs processes to facilitate unprecedented patient care. Furthermore he instills this practice on the new generation of physicians while working tirelessly to advance the educational program at Mount Sinai Hospital by being the Program Director of Surgical Oncology Fellowship.
During the length of his trainings, as well as 2 additional years post residency, Dr. Labow pursued extensive clinical and basic science research. His clinical and research interests include the diagnosis and treatment of a broad range of both primary and metastatic malignancies including gastric and esophageal cancer, pancreatic neoplasms, primary and metastatic liver malignancies, biliary tract disease, colon and rectal cancer, sarcoma, and melanoma. Dr. Labow’s devotion to research and training allow him to understand the entire spectrum of treatments for these cancers, including investigational approaches to help guide each individual patient along the appropriate treatment unique pathway. Moreover, he concentrates in the application of minimally invasive techniques and their role in cancer care.
At Mount Sinai Hospital, Dr. Labow established and directs one of the busiest Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) programs in the country. This technique, which combines surgery with chemotherapy, has revolutionized the treatment of cancers in the abdominal (peritoneal) lining that stem from colon, gastric, ovarian, and appendiceal cancers, as well as mesothelioma and pseudomyxoma peritonei. HIPEC is essentially a chemotherapy "bath" that delivers heated chemotherapy directly into the abdominal cavity, where it penetrates the diseased tissue directly. This targeted contact of the heated drug kills the tumor nodules, which increases absorption of the chemotherapy solution. Dr. Labow, who has performed more than 220 HIPEC procedures since 2007, recognizes the vitality the combination procedure has in significantly extending patient survival rates whilst minimizing the known side effects of chemotherapy that are normally administered intravenously. Additionally, it destroys undetected cancer cells after the tumor has been removed, preventing them from forming into new tumors and causing a reoccurrence of cancer.
Dr. Daniel Labow’s rapport with his patients, his medical knowledge and his dedication as a physician contribute to his reputation with patients as well as other physicians. He is an active member in a number of physician organizations including the American College of Surgeons, American Hepatopancreaticobiliary Association, and Society of Surgical Oncology where he sits on the education committee. As New York State Chair of the Commission on Cancer, Dr. Labow helps shape future cancer initiatives and policy, in addition to Co-Chairing the Gastrointestinal Disease Focus Group at Mount Sinai Hospital. Dr. Labow has been awarded the Robert Paradny Teaching award and was recently named one of New York Metro Area’s Top Doctors by Castle Connolly.
In the News:
CBS Evening News interviews Dr. Labow about rising colorectal cancer cases in young adults
"http://www.fox5ny.com/news/237212998-story"> Dr. Labow shares the incredible story of a Holocaust survivor who also beat cancer
American Board of Surgery
- Colorectal Cancer
- Gallbladder Cancer
- Liver Cancer
MD, Brown University
Residency, General Surgery, University of Chicago Hospitals
Fellowship, Surgery Oncology, Memorial Sloan-Kettering Cancer Center
2011 Top Doctors – New York Metro Area Award
1998 Chief Research Fellow
2007 Robert Paradny Teaching award
2013 Best Doctors
2001 Administrative Chief Resident
Diagnosis and treatment of both primary and metastatic malignancies as well as application of minimally invasive techniques to cancer treatment.
- A phase III study of chemotherapy and chemoradiotherapy with or without hyperacute- pancreatic vaccine in subjects with surgically resected pancreatic cancer
The purpose of this study is to compare the effects, of standard of care therapy (gemcitabine alone or with chemoradiation) with or without the addition of HyperAcute®-Pancreatic Cancer Vaccine to find out which treatment is better.
You may qualify for participation ...
- A phase III study of FOLFIRINOX with or without HyperAcute®-Pancreas (algenpantucel-l) Immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer
The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (either a chemotherapy regimen called FOLFIRINOX or gemcita...
Sarpel U, Bonavia AS, Grucela A, Roayaie S, Schwartz ME, Labow DM. Does Anatomic Versus Nonanatomic Resection Affect Recurrence and Survival in Patients Undergoing Surgery for Colorectal Liver Metastasis?. Annals of Surgical Onology 2008;.
Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, Schwartz ME. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008; 143(3): 366-374.
Cho CS, Labow DM, Gonen M, Jarnagin WR, D'Angelica M, Blumgart L, DeMatteo RP. Impact of Extent of Hepatic Resection for Metastatic Neuroendocrine Carcinoma. Cancer 2008 Jul 1; 113(1): 126-134.
Labow DM, Buell JF, Yoshida A, Rosen S, Posner MC. Isolated pulmonary recurrence after resection of colorectal hepatic metastases--is resection indicated?. Cancer J 8 2002; 8(4): 342-347.
Kammula US, Buell JF, Labow DM, Rosen S, Millis JM, Posner MC. Surgical management of benign tumors of the liver. Int J Gastrointest Cancer 2001; 30(3): 141-146.
Conlon KC, Labow D, Smith A, Jarnagin W, Coit DG, Merchant N, Brennan MF. A prospective randomized clinical trial of the value of intra-peritoneal drainage following pancreatic resection. Annals of Surgery 2001; 234(4): 487-494.
Kaneda Y, Liu D, Brooks A, Abolhoda A, Labow D, Burt ME, Ginsberg RJ. Toxicity and pharmacokinetics of isolated lung perfusion with cisplatin in rat. Japan Journal of Thoracic and Cardiovascular Surgery 2001; 49(7): 443-448.
Buell JF, Rosen S, Yoshida A, Labow D, Limsrichamrern S, Cronin DC, Bruce DS, Wen M, Michelassi F, Millis JM, Posner MC. Hepatic resection: effective treatment for primary and secondary tumors. Surgery 2000; 128(4): 686-693.
Labow D, Lee S, Ginsberg RJ, Crystal RG, Korst RJ. Adenovirus vector-mediated gene transfer to regional lymph nodes. Human Gene Therapy 2000; 11(5): 759-769.
Labow DM, Brennan MF. Gastric Cancer. In: Bayless , Diehl , editors. Advanced Therapy in Gastroenterology and Liver Disease 5/e. BC Decker Inc;.